The Venture Codex

Participated · Series B · Jul 2026

Shexu Technology develops industrial AI generative-design products, including its flagship platform 则形AI, which is built on a self-developed industrial-world model and natural-language large model wrappers to produce cloud-based 3D designs and 2D engineering drawings. The company has upgraded its 3D and 2D product lines into agent-based offerings (geometry AI 3D Agent and manufacturing AI 2D Agent) and is developing a physical AI capability that has reached POC verification. Founding details include a 2020 founding and a CEO/founder Wu Yongrong with a PhD in advanced manufacturing from Tongji University and prior roles at GM advanced manufacturing lab and NIO. Financially, Shexu reported H1 contract value growth of about 70% year-over-year and expects full-year contract value close to ¥200 million, with RAAS contributing roughly one-third of annual revenue. The company plans to internationalize in 2026 with an initial focus on Europe (a seed customer in Germany) and preparations for Japan, Korea and Southeast Asia.

Participated · Series D · Feb 2026

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on improving musculoskeletal health through innovative biologic treatments. Its pipeline currently features three clinical candidates: AGA2118 for postmenopausal osteoporosis, AGA2115 for osteogenesis imperfecta, and AGA111 for spinal fusion. The company recently completed enrollment in its Phase 2 ARTEMIS trial of AGA2118 and has initiated dosing in the Phase 2 IDUN trial evaluating AGA2115. Proceeds from its latest financing will also advance these programs and other undisclosed pipeline assets. Headquartered in Westlake Village, California, Angitia leverages extensive bone biology expertise and rational drug design to address clear unmet medical needs in serious musculoskeletal diseases. No commercial products have been approved yet, reflecting the firm’s clinical-stage status.

Participated · Series A · Jul 2024

Longi Hydrogen was registered in March 2021 and is a holding subsidiary of Longi Green Energy Technology Co., Ltd. The company is positioned as Longi Green Energy’s “second growth curve” and aims to become a global leader in large green‑hydrogen equipment and solutions. Its core products are large alkaline water electrolysis hydrogen‑production devices and green power‑to‑green hydrogen solutions. On June 14 it completed a Series A financing of RMB 1 billion, with a reported post‑money valuation that may exceed RMB 10 billion. Chairman and legal representative Li Zhenguo increased his capital contribution to RMB 2.4 million, raising his stake from 0.2286% to 0.645%.

Participated · Series B · Nov 2023

Dingmao Technology builds enterprise-grade digital-intelligence operations capabilities around its self-developed ARCANA data-intelligence platform and scenario-based intelligent applications. The company positions itself as a provider of a unified new approach to data operations for enterprises. Its product set focuses on automating and optimizing data-driven operational workflows across scenarios. Dingmao recently completed a CNY 100M-level B round, reflecting investor interest in its technology and go-to-market. The company intends to deploy new funding toward continued R&D investment. Management also plans to use the proceeds for market expansion and cross-industry business layout.

Participated · Equity · Jun 2022

NuProbe Global is a genomics and molecular diagnostics company with sites in Houston, TX, Shanghai, and Suzhou. The company develops molecular diagnostic technologies that improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe is led by CEO Yingshuang Chai and co-founder David Zhang, who is also CEO of NuProbe USA. The company raised $50M in funding to support its growth. Proceeds will be used to expand commercial operations, accelerate IVD product clinical studies and regulatory submissions, and develop new genomics and molecular diagnostics technologies. Since its last fundraising in 2021, NuProbe has engaged in research collaborations with several multinational companies and clinical collaborations with over 400 hospitals. NuProbe develops molecular diagnostic technologies and ultrasensitive NGS panels that it says improve detection of sequencing mutations and copy number variations by over 10-fold. The company has signed partnership and licensing deals with Illumina, Qiagen, Oxford Nanopore and the Wego Group, and has begun partnering with pharma companies for clinical research using its Augury™ custom NGS panels. In China’s reproductive health market NuProbe has built collaborations with most top hospitals and is described as a leader in infertility testing. Led by co-founder and CEO Yingshuang Chai, the team includes co-founder and Head of Innovation David Zhang and a scientific advisory board featuring David Walt and George Church. NuProbe operates out of Houston (USA), Shanghai and Suzhou (China). The company plans to expand its commercial teams in the US and China, develop new NGS products, and pursue regulatory approval in China for its clinical products. NuProbe develops toehold probe–based molecular diagnostics technology licensed from Harvard’s Wyss Institute and Rice University to enable highly sensitive, multiplexed detection of disease signatures in cell-free DNA. Its core product focus is on ultra-sensitive, non-invasive blood tests for early cancer detection, infectious disease, and other genomics applications, with platforms intended for cancer, NIPT, and infectious-disease diagnostics. In pre-clinical work the technology improved qPCR and NGS mutation detection sensitivity by 10–100×, achieving limits of detection down to 0.01% and demonstrating multiplexing of 10–100 reactions capable of detecting hundreds of mutations. The proprietary assays are compatible with common PCR and sequencing workflows, which the company says supports clinical applicability. NuProbe plans to use new funding to grow staff in its Cambridge, Mass. and China offices and to continue technology development, clinical trials, and commercialization efforts. Financially, the company recently completed an $11 million Series A to support these development and go-to-market activities.